iBio (IBIO) 10-Q 23 May 16 2016 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Mar. 31, 2016	May. 23, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Entity Registrant Name	iBio, Inc.
Entity Central Index Key	1,420,720
Current Fiscal Year End Date	--06-30
Entity Filer Category	Smaller Reporting Company
Trading Symbol	IBIO
Entity Common Stock, Shares Outstanding		89,109,410

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2016	Jun. 30, 2015
Current assets:
Cash	$ 21,893	$ 9,494
Accounts receivable - trade	454	445
Work in process	58	0
Prepaid expenses and other current assets	318	182
Total current assets	22,723	10,121
Fixed assets, net of accumulated depreciation	25,775	13
Intangible assets, net of accumulated amortization	2,139	2,360
Security deposit	28	0
Total Assets	50,665	12,494
Current liabilities:
Accounts payable (related party of $183 and $153 as of March 31, 2016 and June 30, 2015, respectively)	1,551	1,104
Accrued expenses (related party of $443 and $0 as of March 31, 2016 and June 30, 2015, respectively)	647	159
Capital lease obligation - current portion	167	0
Deferred revenue	76	0
Total Current Liabilities	2,441	1,263
Capital lease obligation - net of current portion	25,308	0
Total Liabilities	$ 27,749	$ 1,263
Commitments and Contingencies
iBio, Inc. Stockholders’ Equity:
Preferred stock - no par value; 1,000,000 shares authorized; no shares issued and outstanding	$ 0	$ 0
Common stock - $0.001 par value; 175,000,000 shares authorized; 82,609,410 and 77,205,410 shares issued and outstanding as of March 31, 2016 and June 30, 2015, respectively	83	77
Additional paid-in capital	63,127	59,006
Accumulated other comprehensive loss	(31)	(25)
Accumulated deficit	(54,914)	(47,827)
Total iBio, Inc. Stockholders’ Equity	8,265	11,231
Noncontrolling interest	14,651	0
Total Equity	22,916	11,231
Total Liabilities and Equity	$ 50,665	$ 12,494

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2016	Jun. 30, 2015
Accounts payable, related parties	$ 183	$ 153
Accrued expenses, related parties	$ 443	$ 0
Preferred stock, par value (in dollars per share)	$ 0	$ 0
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	175,000,000	175,000,000
Common stock, shares issued (in shares)	82,609,410	77,205,410
Common stock, shares outstanding (in shares)	82,609,410	77,205,410

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Revenues	$ 379	$ 349	$ 673	$ 1,535
Operating expenses:
Research and development (related party of $244, $258, $723 and $738)	1,048	815	2,303	2,731
General and administrative (related party of $296, $0 $374 and $0)	2,403	1,222	5,509	3,574
Total operating expenses	3,451	2,037	7,812	6,305
Operating loss	(3,072)	(1,688)	(7,139)	(4,770)
Other income (expense):
Interest expense (related party of $323, $0, $323 and $0)	(323)	0	(323)	0
Interest income	5	2	9	6
Royalty income	5	9	17	24
Total other income (expense)	(313)	11	(297)	30
Consolidated net loss	(3,385)	(1,677)	(7,436)	(4,740)
Net loss attributable to noncontrolling interest	349	0	349	0
Net loss attributable to iBio, Inc.	(3,036)	(1,677)	(7,087)	(4,740)
Comprehensive loss:
Consolidated net loss	(3,385)	(1,677)	(7,436)	(4,740)
Other comprehensive income (loss) - foreign currency translation adjustments	2	(12)	(6)	(26)
Comprehensive loss	$ (3,383)	$ (1,689)	$ (7,442)	$ (4,766)
Loss per common share attributable to iBio, Inc. stockholders - basic and diluted (in dollars per share)	$ (0.04)	$ (0.02)	$ (0.09)	$ (0.07)
Weighted-average common shares outstanding - basic and diluted (in shares)	81,158	72,989	78,587	69,913

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Operating expenses research and development, related party	$ 244	$ 258	$ 723	$ 738
Operating expenses general and administrative, related party	296	0	374	0
Interest Expense, Related Party	$ 323	$ 0	$ 323	$ 0

Condensed Consolidated Stateme6

Condensed Consolidated Statement of Stockholders' Equity - 9 months ended Mar. 31, 2016 - USD ($) $ in Thousands	Total	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]	Noncontrolling Interest [Member]
Balance at Jun. 30, 2015	$ 11,231	$ 0	$ 77	$ 59,006	$ (25)	$ (47,827)	$ 0
Balance (in shares) at Jun. 30, 2015		0	77,206,000
Capital contribution - noncontrolling interest	15,000	$ 0	$ 0	0	0	0	15,000
Sale of common stock	2,178	$ 0	$ 4	2,174	0	0	0
Sale of common stock (in shares)		0	3,500,000
Exercises of warrants	1,009	$ 0	$ 2	1,007	0	0	0
Exercises of warrants (in shares)		0	1,904
Share-based compensation	940	$ 0	$ 0	940	0	0	0
Foreign currency translation adjustment	(6)	0	0	0	(6)	0	0
Net loss	(7,436)	0	0	0	0	(7,087)	(349)
Balance at Mar. 31, 2016	$ 8,265	$ 0	$ 83	$ 63,127	$ (31)	$ (54,914)	$ 14,651
Balance (in shares) at Mar. 31, 2016		0	82,610,000

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities:
Consolidated net loss	$ (7,436)	$ (4,740)
Adjustments to reconcile consolidated net loss to net cash used in operating activities:
Share-based compensation	940	690
Amortization of intangible assets	274	266
Depreciation	263	3
Loss on abandonment of intangible assets	33	47
Changes in operating assets and liabilities
Accounts receivable - trade	(9)	(135)
Accounts receivable - unbilled	0	(325)
Accrued expenses	489	306
Prepaid expenses and other current assets	(136)	(181)
Security deposit	(28)	0
Accounts payable	342	517
Work in process	(58)	0
Deferred revenue	76	34
Net cash used in operating activities	(5,250)	(3,518)
Cash flows from investing activities:
Additions to intangible assets	0	(137)
Purchases of fixed assets	(8)	(15)
Net cash used in investing activities	(8)	(152)
Cash flows from financing activities:
Proceeds from sale of common stock	2,178	7,302
Proceeds from exercise of warrants	1,009	867
Capital contribution - noncontrolling interest	15,000	0
Payment of capital lease obligation	(525)	0
Net cash provided by financing activities	17,662	8,169
Effect of exchange rate changes	(5)	(9)
Net increase in cash	12,399	4,490
Cash - beginning of period	9,494	3,590
Cash - end of period	21,893	8,080
Schedule of non-cash activities:
Purchases of fixed assets financed by capital lease	26,000	0
Unpaid intangible assets included in accounts payable - net	87	0
Unpaid intangible assets included in accrued expenses - net	0	12
Unpaid fixed assets included in accounts payable	17	0
Supplemental cash flow information:
Cash paid during the period for interest	$ 0	$ 0

Nature of Business

Nature of Business	9 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations [Text Block]	1. Nature of Business iBio, Inc. and Subsidiaries (“iBio” or the “Company”) is a biotechnology company focused on the commercialization of its proprietary plant-based protein expression technologies for vaccines and therapeutic proteins and on developing and commercializing select biopharmaceutical product candidates. The advantages of iBio’s technology include reduced production time, capital and operating costs for biopharmaceuticals and the ability to manufacture therapeutic proteins that are difficult or commercially infeasible to produce with conventional methods. iBio was established as a public company in August 2008 as the result of a spinoff from Integrated BioPharma, Inc. The Company operates in one business segment under the direction of its Executive Chairman. The Company’s wholly-owned and majority-owned subsidiaries are as follows: iBioDefense Biologics LLC (“iBioDefense”) – iBioDefense, a wholly-owned subsidiary, is a Delaware limited liability company formed in July 2013 to explore development and commercialization of defense-specific applications of the Company’s proprietary technology. iBioDefense has not commenced any activities to date. iBio Peptide Therapeutics LLC (“iBio Peptide”) – iBio Peptide, a wholly-owned subsidiary, is a Delaware limited liability company formed in November 2013. iBio Peptide has not commenced any activities to date. iBIO DO BRASIL BIOFARMACÊUTICA LTDA. (“iBio Brazil”) – iBio Brazil is a subsidiary organized in Brazil in which the Company has a 99 iBio CMO LLC (“iBio CMO”) – iBio CMO is a Delaware limited liability company formed on December 16, 2015 to develop and manufacture plant-made pharmaceuticals. As of December 31, 2015, the Company owned 100 15 30 70 iBio CMO’s operations take place in Bryan, Texas in a facility controlled by another affiliate of Eastern (the “Second Eastern Affiliate”) as sublandlord. The facility is a 139,000 34

Basis of Presentation

Basis of Presentation	9 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	2. Basis of Presentation Interim Financial Statements The accompanying unaudited condensed consolidated financial statements have been prepared from the books and records of the Company and include all normal and recurring adjustments which, in the opinion of management, are necessary for a fair presentation in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and Rule 8-03 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission. Accordingly, these interim financial statements do not include all of the information and footnotes required for complete annual financial statements. Interim results are not necessarily indicative of the results that may be expected for the full year. Interim unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2015, from which the accompanying condensed consolidated balance sheet dated June 30, 2015 was derived. Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. All intercompany balances and transactions have been eliminated as part of the consolidation. Liquidity The Company's primary sources of liquidity are cash on hand and cash available from the sale of common stock of the Company. At this time, cash flows from operating activities represent net outflows for operating expenses and expenses for technology and product development. As of March 31, 2016, the Company had $ 21.9 4,000,000 6,500,000 Since its spin-off from Integrated BioPharma, Inc. in August 2008, the Company has incurred significant losses and negative cash flows from operations. As of March 31, 2016, the Company's accumulated deficit was $ 54.9 5.2 On May 15, 2015, the Company entered into a common stock purchase agreement with Aspire Capital Fund, LLC (“Aspire Capital”) pursuant to which the Company has the option to require Aspire Capital, upon and subject to the terms of the agreement, to purchase up to $ 15 No shares have been sold under the 2015 Facility as of the date of the filing of this report. See Note 9 for a further description of the agreement . Coincident with the entry into the iBio CMO joint venture, Eastern agreed to acquire 10 0.622 3,500,000 6,500,000 1,784,000 0.53 15 7.2 10 The Company plans to fund its future business operations using cash on hand, through proceeds from the sale of additional equity or other securities, including sales of common stock to Aspire Capital pursuant to the common stock purchase agreement entered into on May 15, 2015, and through proceeds realized in connection with license and collaboration arrangements. The Company cannot be certain that such funding will be available on favorable terms or available at all. To the extent that the Company raises additional funds by issuing equity securities, its stockholders may experience significant dilution. The Company's financial statements were prepared under the assumption that the Company will continue as a going concern. If the Company is unable to raise funds when required or on favorable terms, this assumption may no longer be operative, and the Company may have to: a) significantly delay, scale back, or discontinue the product application and/or commercialization of its proprietary technologies; b) seek collaborators for its technology and product candidates on terms that are less favorable than might otherwise be available; c) relinquish or otherwise dispose of rights to technologies, product candidates, or products that it would otherwise seek to develop or commercialize; or d) possibly cease operations .

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	3. Summary of Significant Accounting Policies The Company’s significant accounting policies are described in Note 3 of the Notes to Financial Statements in the Annual Report on Form 10-K for the year ended June 30, 2015. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of intellectual property, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates. The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed or determinable, and collectability is reasonably assured. Deferred revenue represents billings to a customer to whom the services have not yet been provided. The Company’s contract revenue consists primarily of amounts earned under contracts with third-party customers and reimbursed expenses under such contracts. The Company analyzes its agreements to determine whether the elements can be separated and accounted for individually or as a single unit of accounting in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 605-25, “ Revenue Arrangements with Multiple Deliverables Revenue Recognition The Company generates (or may generate in the future) contract revenue under the following types of contracts: Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured. Time and Materials Under a time and materials contract, the Company charges customers an hourly rate plus reimbursement for other project specific costs. The Company recognizes revenue for time and material contracts based on the number of hours devoted to the project multiplied by the customer’s billing rate plus other project specific costs incurred. Grant Income Grants are recognized as income when all conditions of such grants are fulfilled or there is a reasonable assurance that they will be fulfilled. Grant income is classified as a reduction of research and development expenses. For both the three and nine months ended March 31, 2016, grant income amounted to approximately $ 9,000 Work in process consists primarily of the cost of labor and other overhead incurred on contracts that have not been completed as of March 31, 2016. The Company accounts for research and development costs in accordance with the FASB ASC 730-10, “ Research and Development The Company accounts for foreign currency translation pursuant to FASB ASC 830, “ Foreign Currency Matters In May 2014, ASU No. 2014-09, “ Revenue from Contracts with Customers Revenue Recognition Revenue from Contracts with Customers The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. ASU 2014-09 was scheduled to be effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. In August 2015, the FASB issued ASU 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of Effective Date” Effective January 1, 2016, the Company adopted ASU 2014-12, “ Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period In June 2014, ASU 2014-15, “ Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern Effective January 1, 2016, the Company adopted ASU 2015-01, “ Income Statement - Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items” In April 2015, the FASB issued ASU 2015-03, “ Interest – Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs Elements of Financial Statements In November 2015, the FASB issued ASU 2015-17, “ Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes In January 2016, the FASB issued ASU 2016-01, “ Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU 2016-02, “ Leases (Topic 842) Leases (Topic 840) In March 2016, the FASB issued ASU 2016-09, “ Improvements to Employee Share-Based Payment Accounting In April 2016, the FASB issued ASU 2016-10, “ Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing “Revenue from Contracts with Customers.” Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying financial statements.

Financial Instruments and Fair

Financial Instruments and Fair Value Measurement	9 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	4. Financial Instruments and Fair Value Measurement The carrying values of cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses in the Company's condensed consolidated balance sheets approximated their fair values as of March 31, 2016 and June 30, 2015 due to their short-term nature. The carrying value of the capital lease obligation approximated its fair value at March 31, 2016 as the interest rate used to discount the lease payments approximated market.

Fixed Assets and Capital Lease

Fixed Assets and Capital Lease Obligations	9 Months Ended
	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	5. Fixed Assets and Capital Lease Obligations Assets held under the terms of capital leases are included in fixed assets and are depreciated on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under capital leases are shown within liabilities and are analyzed between amounts falling due within and after one year (see Note 8). As discussed above, iBio CMO is leasing its facility in Bryan, Texas as well as certain equipment from the Second Affiliate under a 34 The economic substance of the sublease is that the Company is financing the acquisition of the facility and equipment and accordingly, the facility and equipment are recorded as assets and the lease is recorded as a liability. As the sublease involves real estate and equipment, the Company separated the equipment component and accounted for the facility and equipment as if each was leased separately. March 31, June 30, (Unaudited) Facility under capital lease $ 20,000 $ - Equipment under capital lease 6,000 - Facility improvements 21 - Office equipment 44 40 26,065 40 Accumulated depreciation – assets under capital lease (259) - Accumulated depreciation – other (31) (27) (290) (27) Net fixed assets $ 25,775 $ 13 Depreciation expense was approximately $ 260,000 1,100 263,000 3,000 259,000

Intangible Assets

Intangible Assets	9 Months Ended
	Mar. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]	6. Intangible Assets The Company has two categories of intangible assets – intellectual property and patents. Intellectual property consists of all technology, know-how, data, and protocols for producing targeted proteins in plants and related to any products and product formulations for pharmaceutical uses and for other applications. Intellectual property includes, but is not limited to, certain technology for the development and manufacture of novel vaccines and therapeutics for humans and certain veterinary applications acquired in December 2003 from Fraunhofer USA Inc., acting through its Center for Molecular Biotechnology (“Fraunhofer”), pursuant to a Technology Transfer Agreement, as amended (the “TTA”). The Company designates such technology acquired from Fraunhofer as iBioLaunch technology or as iBioModulator technology. The value attributed to Patents owned or controlled by the Company is based on payments for services and fees related to the further development and protection of the Company’s patent portfolio. In January 2014, the Company entered into a license agreement with a U.S. university whereby iBio acquired exclusive worldwide rights to certain issued and pending patents covering specific candidate products for the treatment of fibrosis (the “Licensed Technology”). The license agreement provides for payment by the Company of a license issue fee, annual license maintenance fees, reimbursement of prior patent costs incurred by the university, payment of a milestone payment upon regulatory approval for sale of a first product, and annual royalties on product sales. In addition, the Company has agreed to meet certain diligence milestones related to product development benchmarks. As part of its commitment to the diligence milestones, the Company successfully commenced production of a plant-made peptide comprising the Licensed Technology before March 31, 2014. The next milestone – filing a New Drug Application with the FDA covering the Licensed Technology – became due on December 1, 2015. A six-month extension was automatically granted until June 1, 2016 under the license agreement. The Company and the university expect to replace the original milestone schedule with a new one within the next quarter based on technical changes to the development program and a revised forecast of completion dates. The Company accounts for intangible assets at their historical cost and records amortization utilizing the straight-line method based upon their estimated useful lives. Patents are amortized over a period of ten years and other intellectual property is amortized over a period from 16 23 March 31, June 30, (Unaudited) Intellectual property – gross carrying value $ 3,100 $ 3,100 Patents – gross carrying value 2,223 2,181 5,323 5,281 Intellectual property – accumulated amortization (1,893) (1,776) Patents – accumulated amortization (1,291) (1,145) (3,184) (2,921) Net intangible assets $ 2,139 $ 2,360 Amortization expense was approximately $ 92 88 274 266 16 33 17 47

Significant Vendor

Significant Vendor	9 Months Ended
	Mar. 31, 2016
Significant Vendor [Abstract]
Significant Vendor Disclosures [Text Block]	7. Significant Vendor Fraunhofer was the Company’s most significant vendor solely on the basis of the three-party Yellow Fever vaccine development program among Fiocruz/Bio-Manguinhos, the Company, and Fraunhofer (described in greater detail below). The accounts payable balance under this three-party agreement includes amounts due Fraunhofer of approximately $ 417,000 445,000 357,000 348,000 635,000 1,535,000 Other than for final completion of the current phase of the Yellow Fever vaccine program, the Company is not reliant on Fraunhofer as a vendor. The Company obtains the majority of the services it requires for both its own product development and for work it performs for clients from its subsidiary company, iBio CMO LLC and from Novici Biotech LLC. The Company obtains new intellectual property and patent rights from iBio CMO LLC, Novici Biotech LLC, and other contractors and academic collaborators and/or licensors. In September 2013, the Company and Fraunhofer completed the Terms of Settlement for the TTA Seventh Amendment (the “Settlement Agreement”), the significant terms of which are as follows: ⋅ The Company’s liabilities to Fraunhofer in the amount of approximately $ 2.9 ⋅ The Company’s obligation under the TTA, prior to the Settlement Agreement, to make three $ 1 3 December 31, 2015 ⋅ The Company terminated and released Fraunhofer from the obligation to make further financial contributions toward the enhancement, improvement and expansion of iBio’s technology in an amount at least equal to the Guaranteed Annual Payments. In addition, the Company terminated and released Fraunhofer from the obligation to further reimburse iBio for certain past and future patent-related expenses; ⋅ The Company’s obligation to remit to Fraunhofer minimum annual royalty payments in the amount of $ 200,000 4 ⋅ The rate at which the Company will be obligated to pay royalties to Fraunhofer on iBioLaunch ™ ™ ⋅ Any and all other claims of each party to any other amounts due at June 30, 2013 were mutually released. The effect of the Settlement Agreement was the elimination of approximately $ 1.7 1.2 1 1.9 1.9 1.04 0.7 122,000 On January 4, 2011, the Company entered into the Collaboration and License Agreement (the “CLA”) which is a three party agreement involving the Company, Fraunhofer and FioCruz, a public entity, member of the Indirect Federal Public Administration and linked to the Health Ministry of Brazil, acting through its unit Bio-Manguinhos. The CLA provides for the development of a yellow fever vaccine to be manufactured and distributed within Latin America and Africa by FioCruz. The CLA was supplemented by a bilateral agreement between iBio and Fraunhofer dated December 27, 2010 in which the Company engaged Fraunhofer as a contractor to provide the research and development services (both, together, the “Agreement”). The services are billed to FioCruz at Fraunhofer’s cost, so the Company’s revenue is equivalent to expense and there is no profit. On June 12, 2014, FioCruz, Fraunhofer and iBio executed an amendment to the Agreement (the “Amended Agreement”) which provides for revised research and development, work plans, reporting, objectives, estimated budget, and project billing process. For the three months ended March 31, 2016 and 2015, under the Amended Agreement, the Company recognized revenue of $ 357,000 348,000 635,000 1,535,000 On March 17, 2015 the Company filed a Verified Complaint in the Court of Chancery of the State of Delaware against Fraunhofer and Vidadi Yusibov, Fraunhofer’s Executive Director. See Note 14 - Lawsuits for additional information.

Capital Lease Obligation

Capital Lease Obligation	9 Months Ended
	Mar. 31, 2016
Leases, Capital [Abstract]
Leases of Lessee Disclosure [Text Block]	8. Capital Lease Obligation As discussed above, iBio CMO is leasing its facility in Bryan, Texas as well as certain equipment from the Second Affiliate under a 34 2,100,000 The base rent under the sublease will be increased by any increase in the base rent under the ground lease as a result of such adjustments. In addition to the base rent, iBio CMO is required to pay, for each calendar year during the term, a portion of the total gross sales for products manufactured or processed at the facility, equal to 7% of the first $5,000,000 of gross sales, 6% of gross sales between $5,000,001 and $25,000,000, 5% of gross sales between $25,000,001 and $50,000,000, 4% of gross sales between $50,000,001 and $100,000,000, and 3% of gross sales between $100,000,001 and $500,000,000. However, if for any calendar year period from January 1, 2018 through December 31, 2019, iBio CMO’s applicable gross sales are less than $5,000,000, or for any calendar year period from and after January 1, 2020, its applicable gross sales are less than $10,000,000 Interest expense incurred under the capital lease obligation amounted to $ 323,000 0 323,000 0 Fiscal period ending on: Principal Interest Total March 31, 2017 $ 166,649 $ 1,933,351 $ 2,100,000 March 31, 2018 179,693 1,920,307 2,100,000 March 31, 2019 193,758 1,906,242 2,100,000 March 31, 2020 208,924 1,891,076 2,100,000 March 31, 2021 225,277 1,874,723 2,100,000 Thereafter 24,500,699 36,399,301 60,900,000 Total minimum lease payments 25,475,000 $ 45,925,000 $ 71,400,000 Less: current portion (166,649) Long-term portion of minimum lease obligations $ 25,308,351

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Mar. 31, 2016
Stockholders Equity Note [Abstract]
Stockholders Equity Note Disclosure [Text Block]	9. Stockholders’ Equity Preferred Stock The Company’s Board of Directors is authorized to issue, at any time, without further stockholder approval, up to 1 Common Stock As of March 31, 2016 and June 30, 2015, the Company was authorized to issue up to 175 approximately 82.6 77.2 30,000 Issuances of common stock were as follows: Aspire Capital – 2015 Facility On May 15, 2015, the Company entered into a common stock purchase agreement (the “2015 Aspire Purchase Agreement”) with Aspire Capital, pursuant to which the Company has the option to require Aspire Capital to purchase up to an aggregate of $ 15.0 450,000 (the “Commitment Shares”) . On any business day after the Commencement Date (as defined below) and over the 36-month term of the 2015 Aspire Purchase Agreement, the Company has the right, in its sole discretion, to present Aspire Capital with a purchase notice (each, a “Purchase Notice”) directing Aspire Capital to purchase up to 200,000 500,000 2,000,000 In addition, on any date on which the Company submits a Purchase Notice to Aspire Capital for at least 150,000 0.40 35 97 80 The number of Purchase Shares covered by and timing of each Purchase Notice or VWAP Purchase Notice are determined at the Company’s discretion. The aggregate number of shares that the Company can sell to Aspire Capital under the 2015 Aspire Purchase Agreement may in no case exceed 15,343,406 19.99 450,000 The 2015 Aspire Purchase Agreement contains customary representations, warranties, covenants, closing conditions and indemnification and termination provisions. Sales under the 2015 Aspire Purchase Agreement could commence only after certain conditions were satisfied (the date on which all requisite conditions have been satisfied being referred to as the “Commencement Date”), which conditions included the delivery to Aspire Capital of a prospectus supplement covering the Commitment Shares and the Purchase Shares, approval for listing on NYSE MKT of the Purchase Shares and the Commitment Shares, the issuance of the Commitment Shares to Aspire Capital, and the receipt by Aspire Capital of a customary opinion of counsel and other certificates and closing documents. Either party had the option to terminate the 2015 Aspire Purchase Agreement in the event the Commencement Date had not occurred by July 1, 2015. The 2015 Aspire Purchase Agreement may be terminated by the Company at any time, at its discretion, without any cost or penalty. The Company’s net proceeds will depend on the Purchase Price, the VWAP Purchase Price and the frequency of the Company’s sales of Purchase Shares to Aspire Capital; subject to the maximum $ 15.0 In connection with the 2015 Aspire Purchase Agreement, the Company also entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with Aspire Capital, dated May 15, 2015. The Registration Rights Agreement provides, among other things, a requirement to register the sale of the Commitment Shares and the Purchase Shares to Aspire Capital pursuant to the Company’s existing shelf registration statement (the “Registration Statement”). The Company further agreed to keep the Registration Statement effective and to indemnify Aspire Capital for certain liabilities in connection with the sale of the Securities under the terms of the Registration Rights Agreement. On May 29, 2015, the Company filed a prospectus supplement to the Company’s existing Registration Statement on Form S-3, registering $ 15.0 No shares have been sold under the 2015 Facility as of the date of the filing of this report. Eastern – Share Purchase Agreements On January 13, 2016, the Company entered into a share purchase agreement with Eastern pursuant to which Eastern agreed to purchase 3,500,000 0.622 2,178,000 1,784,000 0.53 945,520 On January 13, 2016, the Company entered into a separate share purchase agreement with Eastern pursuant to which Eastern agreed to purchase 6,500,000 0.622 6,500,000 4,043,000 38 Warrants The Company has historically financed its operations through the sale of common stock and warrants, sold together as units. Warrants Weighted- Outstanding as of July 1, 2015 6,633,324 $ 1.38 Exercised (1,904,000) $ 0.53 Expired (4,699,324) $ 2.09 Outstanding and exercisable as of March 31, 2016 30,000 $ 0.53 Exercises of Warrants During the period from July 1, 2015 to September 30, 2015, t he Company issued 120,000 63,000 As discussed above, in January 2016, Eastern exercised warrants to acquire 1,784,000

Earnings (Loss) Per Common Shar

Earnings (Loss) Per Common Share	9 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	10. Earnings (Loss) Per Common Share Basic earnings (loss) per common share is computed by dividing the net income (loss) allocated to common stockholders by the weighted-average number of shares of common stock outstanding during the period. For purposes of calculating diluted earnings (loss) per common share, the denominator includes both the weighted-average number of shares of common stock outstanding during the period and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common stock equivalents potentially include stock options and warrants using the treasury stock method. Three Months ended Nine Months ended March 31, March 31, 2016 2015 2016 2015 Basic and diluted numerator: Net loss available to iBio, Inc. stockholders $ (3,036) $ (1,677) $ (7,087) $ (4,740) Basic and diluted denominator: Weighted-average common shares outstanding 81,158 72,989 78,587 69,913 Per share amount $ (0.04) $ (0.02) $ (0.09) $ (0.07) For the three and nine months ended March 31, 2016 and 2015, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per common share is the same. As of March 31, 2016, shares issuable which could potentially dilute future earnings included approximately 12.3 30,000 9.7 6.6

Share-Based Compensation

Share-Based Compensation	9 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	11. Share-Based Compensation Three Months Ended March 31, 2016 2015 Research and development $ 6 $ - General and administrative 291 224 Totals $ 297 $ 224 Nine Months Ended March 31, 2016 2015 Research and development $ 15 $ - General and administrative 925 690 Totals $ 940 $ 690 Stock Options On August 12, 2008, the Company adopted the iBioPharma 2008 Omnibus Equity Incentive Plan (the “Plan”) for employees, officers, directors and external service providers. The original Plan provided that the Company may grant options to purchase stock and/or make awards of restricted stock up to an aggregate amount of 10 2.9 On September 4, 2015 and March 1, 2016, the Company granted stock options to members of the Board of Directors, officers and employees to purchase 2.75 1.64 Weighted- Weighted- average average Remaining Aggregate Stock Exercise Contractual Intrinsic Value Options Price Term (in years) (in thousands) Outstanding as of July 1, 2015 9,523,334 $ 1.22 6.6 $ 1,848 Granted 2,750,000 1.64 Outstanding as of March 31, 2016 12,273,334 $ 1.31 6.6 $ 479 Vested and, as of March 31, 2016, expected to vest 12,212,641 $ 1.31 6.6 $ 479 Exercisable as of March 31, 2016 7,455,024 $ 1.31 5.3 $ 417 The weighted-average grant date fair value of stock options granted during the nine months ended March 31, 2016 was $ 0.62 1.9 2.0 Risk-free interest rate 1.83% - 2.13 % Dividend yield 0 % Volatility 109.49% - 112.17 % Expected term (in years) 9

Related Party Transactions

Related Party Transactions	9 Months Ended
	Mar. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	12. Related Party Transactions Novici Biotech, LLC In January 2012, the Company entered into an agreement with Novici Biotech, LLC (“Novici”) in which iBio’s President is a minority stockholder. Novici performs laboratory feasibility analyses of gene expression, protein purification and preparation of research samples. In addition, the Company and Novici collaborate on the development of new technologies and product candidates for exclusive worldwide commercial use by the Company. The accounts payable balance includes amounts due to Novici of approximately $ 183,000 153,000 244,000 258,000 723,000 738,000 28,882 Agreements with Eastern Capital Limited and its Affiliates. As more fully discussed in Note 9, the Company entered into two share purchase agreements with Eastern and sold 10 0.622 6,220,000 1,784,000 0.53 945,520 Concurrently with the execution of the Purchase Agreements, iBio entered into a contract manufacturing joint venture with an affiliate of Eastern to develop and manufacture plant-made pharmaceuticals through iBio’s recently formed subsidiary, iBio CMO. The Eastern Affiliate contributed $ 15.0 30 70 technologies In connection with the joint venture, the Second Eastern Affiliate, which controls the subject property as sublandlord, granted iBio CMO a 34 443,000 296,000 374,000 323,000 A three-year standstill agreement (the “Standstill Agreement”) that will take effect upon issuance of the Eastern Shares pursuant to the 6.5 38 Operating Lease with Minority Stockholder Effective January 1, 2015, the Company is leasing office space on a month-to-month basis from an entity owned by a minority stockholder of the Company for approximately $ 2,000

Income Taxes

Income Taxes	9 Months Ended
	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	13. Income Taxes The Company recorded no income tax expense for the nine months ended March 31, 2016 and 2015 because the estimated annual effective tax rate was zero. As of March 31, 2016, the Company continues to provide a valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	14. Commitments and Contingencies Agreements Under the terms of the Settlement Agreement described in Note 7 – Significant Vendor, the Company undertook to engage Fraunhofer for at least $ 3 1.5 0.5 On June 12, 2014, FioCruz, Fraunhofer and iBio executed an amendment to the CLA (the “Amended Agreement”) to create a new research and development plan for the development of a recombinant yellow fever vaccine providing revised reporting, objectives, estimated budget, and project billing process. Under the CLA and bilateral agreement between iBio and Fraunhofer dated December 27, 2010, Fraunhofer, which has been engaged to act as the Company’s subcontractor for performance of research and development services for the new research and development plan, will bill FioCruz directly on behalf of the Company at the rates, amounts and times provided in the Amended Agreement, and the proceeds of such billings and only the proceeds will be paid to Fraunhofer for its services so the Company’s expense is equal to its revenue and no profit is recognized for these activities under the Amended Agreement. For the year ended June 30, 2015, $ 2.1 3.0 Under the terms of the TTA (described in Note 7 – Significant Vendor) and for a period of 15 years, the Company shall pay Fraunhofer one percent (1%) of all receipts derived by the Company from sales of products produced utilizing the iBioLaunch or iBioModulator technology and ten percent (10%) of all receipts derived by the Company from licensing either of those technologies to third parties. 4 On January 14, 2014 (the “Effective Date”), the Company entered into an exclusive worldwide License Agreement (“LA”) with the University of Pittsburgh (“UP”) covering all of the U.S. and foreign patents and patent applications and related intellectual property owned by UP pertinent to the use of endostatin peptides for the treatment of fibrosis. The Company paid an initial license fee of $ 20,000 30,627 25,000 150,000 On December 30, 2013, the Company entered into a Project Agreement with the Medical University of South Carolina (“MUSC”) providing for the performance of research and development services by MUSC related to peptides for the treatment of fibrosis. The agreement requires the Company to make payments totaling $ 78,000 December 31, 2015 161,754 New Lease As discussed above, iBio CMO is leasing its facility in Bryan, Texas from the Second Affiliate under a 34 Lawsuits On October 22, 2014, the Company filed a Verified Complaint in the Court of Chancery of the State of Delaware against PlantForm Corporation (“PlantForm”) and PlantForm’s president seeking equitable relief and damages based upon PlantForm’s interference with several contracts between the Company and Fraunhofer USA’s Center for Molecular Biotechnology unit (“Fraunhofer”) and one of the Company’s consultants and misappropriating the Company’s intellectual property including trade secrets and know-how. On May 14, 2015, after mediation ordered and supervised by the Chancery Court, PlantForm represented and agreed that all drug development and manufacturing activities of PlantForm with Fraunhofer had ceased and would not be renewed at least until after the termination of the Company’s litigation regarding similar subject matter with Fraunhofer, and all of the accrued claims between the Company and PlantForm and its President were voluntarily dismissed with prejudice. On March 17, 2015 the Company filed a Verified Complaint in the Court of Chancery of the State of Delaware against Fraunhofer and Vidadi Yusibov (“Yusibov”), Fraunhofer’s Executive Director, seeking monetary damages and equitable relief based on Fraunhofer’s material and continuing breaches of their contracts with the Company. On September 16, 2015, the Company voluntarily dismissed its action against Yusibov, without prejudice, and thereafter on September 29, 2015, the Company filed a Verified Amended Complaint against Fraunhofer alleging material breaches by Fraunhofer of its agreements with the Company and seeking monetary damages and equitable relief against Fraunhofer. Briefing has been completed on a motion to dismiss filed by Fraunhofer in lieu of filing an answer to the complaint. Fraunhofer also has moved for a protective order in connection with certain discovery served by iBio. At the Court’s suggestion, the parties have agreed to brief, before the Court decides the motion for protective order, their respective positions on the scope of iBio’s rights under the parties’ agreements. The Court heard oral argument on this threshold issue on April 29, 2016. The Company is unable to predict the ultimate outcome of this action at this time. On October 24, 2014, a putative class action captioned Juan Pena, Individually and on Behalf of All Others Similarly Situated v. iBio, Inc. and Robert B. Kay Vamsi Andavarapu, Individually And On Behalf Of All Others Situated v. iBio, Inc., Robert B. Kay, and Robert Erwin 1,875,000 On December 4, 2015, a putative derivative action captioned Savage, Derivatively on Behalf of iBio, Inc., Plaintiff, v. Robert B. Kay, Arthur Y. Elliott, James T. Hill, Glenn Chang, Philip K. Russell, John D. McKey, and Seymour Flug, Defendants, and iBio, Inc., Nominal Defendant

Segment Reporting

Segment Reporting	9 Months Ended
	Mar. 31, 2016
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	15. Segment Reporting As discussed above, iBio Brazil began operations in the first quarter of fiscal 2015. In accordance with FASB ASC 280, “ Segment Reporting Three months ended March 31, 2016 United States Brazil Total Net revenues $ 379 $ - $ 379 Research and development expenses 1,048 - 1,048 General and administrative expenses 2,398 5 2,403 Operating loss (3,067) (5) (3,072) Three months ended March 31, 2015 United States Brazil Total Net revenues $ 349 $ - $ 349 Research and development expenses 815 - 815 General and administrative expenses 1,187 35 1,222 Operating loss (1,653) (35) (1,688) Nine months ended March 31, 2016 United States Brazil Total Net revenues $ 673 $ - $ 673 Research and development expenses 2,303 - 2,303 General and administrative expenses 5,492 17 5,509 Operating loss (7,122) (17) (7,139) Nine months ended March 31, 2015 United States Brazil Total Net revenues $ 1,535 $ - $ 1,535 Research and development expenses 2,731 - 2,731 General and administrative expenses 3,488 86 3,574 Operating loss (4,684) (86) (4,770) Total Assets for the Business Segments United States Brazil Total March 31, 2016 (unaudited) $ 50,642 $ 23 $ 50,665 June 30, 2015 12,448 46 12,494

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of intellectual property, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed or determinable, and collectability is reasonably assured. Deferred revenue represents billings to a customer to whom the services have not yet been provided. The Company’s contract revenue consists primarily of amounts earned under contracts with third-party customers and reimbursed expenses under such contracts. The Company analyzes its agreements to determine whether the elements can be separated and accounted for individually or as a single unit of accounting in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 605-25, “ Revenue Arrangements with Multiple Deliverables Revenue Recognition The Company generates (or may generate in the future) contract revenue under the following types of contracts: Fixed-Fee Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured. Time and Materials Under a time and materials contract, the Company charges customers an hourly rate plus reimbursement for other project specific costs. The Company recognizes revenue for time and material contracts based on the number of hours devoted to the project multiplied by the customer’s billing rate plus other project specific costs incurred. Grant Income Grants are recognized as income when all conditions of such grants are fulfilled or there is a reasonable assurance that they will be fulfilled. Grant income is classified as a reduction of research and development expenses. For both the three and nine months ended March 31, 2016, grant income amounted to approximately $ 9,000
Inventory Work in Process, Policy [Policy Text Block]	Work in Process Work in process consists primarily of the cost of labor and other overhead incurred on contracts that have not been completed as of March 31, 2016.
Research and Development Expense, Policy [Policy Text Block]	Research and Development The Company accounts for research and development costs in accordance with the FASB ASC 730-10, “ Research and Development
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency The Company accounts for foreign currency translation pursuant to FASB ASC 830, “ Foreign Currency Matters
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In May 2014, ASU No. 2014-09, “ Revenue from Contracts with Customers Revenue Recognition Revenue from Contracts with Customers The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. ASU 2014-09 was scheduled to be effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. In August 2015, the FASB issued ASU 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of Effective Date” Effective January 1, 2016, the Company adopted ASU 2014-12, “ Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period In June 2014, ASU 2014-15, “ Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern Effective January 1, 2016, the Company adopted ASU 2015-01, “ Income Statement - Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items” In April 2015, the FASB issued ASU 2015-03, “ Interest – Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs Elements of Financial Statements In November 2015, the FASB issued ASU 2015-17, “ Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes In January 2016, the FASB issued ASU 2016-01, “ Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU 2016-02, “ Leases (Topic 842) Leases (Topic 840) In March 2016, the FASB issued ASU 2016-09, “ Improvements to Employee Share-Based Payment Accounting In April 2016, the FASB issued ASU 2016-10, “ Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing “Revenue from Contracts with Customers.” Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying financial statements.

Fixed Assets and Capital Leas24

Fixed Assets and Capital Lease Obligations (Tables)	9 Months Ended
	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	The following table summarizes by category the gross carrying value and accumulated depreciation of fixed assets (in thousands): March 31, June 30, (Unaudited) Facility under capital lease $ 20,000 $ - Equipment under capital lease 6,000 - Facility improvements 21 - Office equipment 44 40 26,065 40 Accumulated depreciation – assets under capital lease (259) - Accumulated depreciation – other (31) (27) (290) (27) Net fixed assets $ 25,775 $ 13

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Mar. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	The following table summarizes by category the gross carrying value and accumulated amortization of intangible assets (in thousands): March 31, June 30, (Unaudited) Intellectual property – gross carrying value $ 3,100 $ 3,100 Patents – gross carrying value 2,223 2,181 5,323 5,281 Intellectual property – accumulated amortization (1,893) (1,776) Patents – accumulated amortization (1,291) (1,145) (3,184) (2,921) Net intangible assets $ 2,139 $ 2,360

Capital Lease Obligation (Table

Capital Lease Obligation (Tables)	9 Months Ended
	Mar. 31, 2016
Table Text Block Supplement [Abstract]
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]	Fiscal period ending on: Principal Interest Total March 31, 2017 $ 166,649 $ 1,933,351 $ 2,100,000 March 31, 2018 179,693 1,920,307 2,100,000 March 31, 2019 193,758 1,906,242 2,100,000 March 31, 2020 208,924 1,891,076 2,100,000 March 31, 2021 225,277 1,874,723 2,100,000 Thereafter 24,500,699 36,399,301 60,900,000 Total minimum lease payments 25,475,000 $ 45,925,000 $ 71,400,000 Less: current portion (166,649) Long-term portion of minimum lease obligations $ 25,308,351

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Mar. 31, 2016
Stockholders Equity Note [Abstract]
Schedule of Stockholders Equity Note, Warrants or Rights [Table Text Block]	The following table summarizes all warrant activity for the nine months ended March 31, 2016: Warrants Weighted- Outstanding as of July 1, 2015 6,633,324 $ 1.38 Exercised (1,904,000) $ 0.53 Expired (4,699,324) $ 2.09 Outstanding and exercisable as of March 31, 2016 30,000 $ 0.53

Earnings (Loss) Per Common Sh28

Earnings (Loss) Per Common Share (Tables)	9 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts): Three Months ended Nine Months ended March 31, March 31, 2016 2015 2016 2015 Basic and diluted numerator: Net loss available to iBio, Inc. stockholders $ (3,036) $ (1,677) $ (7,087) $ (4,740) Basic and diluted denominator: Weighted-average common shares outstanding 81,158 72,989 78,587 69,913 Per share amount $ (0.04) $ (0.02) $ (0.09) $ (0.07)

Share-Based Compensation (Table

Share-Based Compensation (Tables)	9 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	The following table summarizes the components of share-based compensation expense in the condensed consolidated statements of operations (in thousands): Three Months Ended March 31, 2016 2015 Research and development $ 6 $ - General and administrative 291 224 Totals $ 297 $ 224 Nine Months Ended March 31, 2016 2015 Research and development $ 15 $ - General and administrative 925 690 Totals $ 940 $ 690
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table summarizes all stock option activity during the nine months ended March 31, 2016: Weighted- Weighted- average average Remaining Aggregate Stock Exercise Contractual Intrinsic Value Options Price Term (in years) (in thousands) Outstanding as of July 1, 2015 9,523,334 $ 1.22 6.6 $ 1,848 Granted 2,750,000 1.64 Outstanding as of March 31, 2016 12,273,334 $ 1.31 6.6 $ 479 Vested and, as of March 31, 2016, expected to vest 12,212,641 $ 1.31 6.6 $ 479 Exercisable as of March 31, 2016 7,455,024 $ 1.31 5.3 $ 417
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The Company estimated the fair value of options granted using the Black-Scholes option pricing model with the following assumptions: Risk-free interest rate 1.83% - 2.13 % Dividend yield 0 % Volatility 109.49% - 112.17 % Expected term (in years) 9

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended
	Mar. 31, 2016
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Geographic segments are components of an enterprise about which separate financial information is available and regularly evaluated by the chief operating decision maker in deciding how to allocate resources and in assessing performance. Three months ended March 31, 2016 United States Brazil Total Net revenues $ 379 $ - $ 379 Research and development expenses 1,048 - 1,048 General and administrative expenses 2,398 5 2,403 Operating loss (3,067) (5) (3,072) Three months ended March 31, 2015 United States Brazil Total Net revenues $ 349 $ - $ 349 Research and development expenses 815 - 815 General and administrative expenses 1,187 35 1,222 Operating loss (1,653) (35) (1,688) Nine months ended March 31, 2016 United States Brazil Total Net revenues $ 673 $ - $ 673 Research and development expenses 2,303 - 2,303 General and administrative expenses 5,492 17 5,509 Operating loss (7,122) (17) (7,139) Nine months ended March 31, 2015 United States Brazil Total Net revenues $ 1,535 $ - $ 1,535 Research and development expenses 2,731 - 2,731 General and administrative expenses 3,488 86 3,574 Operating loss (4,684) (86) (4,770) Total Assets for the Business Segments United States Brazil Total March 31, 2016 (unaudited) $ 50,642 $ 23 $ 50,665 June 30, 2015 12,448 46 12,494

Nature of Business (Details Tex

Nature of Business (Details Textual) $ in Millions	9 Months Ended
	Mar. 31, 2016ft²	Jan. 13, 2016USD ($)	Dec. 31, 2015
Nature of Business [Line Items]
Number of Operating Segments	1
BRAZIL
Nature of Business [Line Items]
Equity Method Investment, Ownership Percentage	99.00%
Second Eastern Affilate [Member]
Nature of Business [Line Items]
Area of Land | ft²	139,000
iBio CMO LLC [Member] | Second Eastern Affilate [Member]
Nature of Business [Line Items]
Lease Term	34 years
iBio CMO [Member]
Nature of Business [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent			100.00%
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners		70.00%
iBio CMO [Member] | Second Eastern Affilate [Member]
Nature of Business [Line Items]
Noncontrolling Interest, Preferred Stock Amount | $		$ 15
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners		30.00%

Basis of Presentation (Details

Basis of Presentation (Details Textual) - USD ($)	May. 15, 2015	Apr. 30, 2016	Apr. 13, 2016	Jan. 25, 2016	Mar. 31, 2016	Mar. 31, 2015	Jun. 30, 2015	Jun. 30, 2014
Basis of Presentation [Line Items]
Accumulated deficit					$ (54,914,000)		$ (47,827,000)
Net Cash Used in Operating Activities					(5,250,000)	$ (3,518,000)
Stock Issued During Period, Value, New Issues					2,178,000
Cash and Cash Equivalents, at Carrying Value, Total					$ 21,893,000	$ 8,080,000	$ 9,494,000	$ 3,590,000
Common Stock, Par or Stated Value Per Share					$ 0.001		$ 0.001
Class Of Warrants Or Rights Exercised					1,904,000
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.53		$ 1.38
Subsequent Event [Member]
Basis of Presentation [Line Items]
Stock Issued During Period, Shares, New Issues		6,500,000	6,500,000
Stock Issued During Period, Value, New Issues		$ 4,000,000	$ 4,043,000
Subsequent Event [Member] | Stockholders [Member]
Basis of Presentation [Line Items]
Stock Issued During Period, Shares, Other		6,500,000
Aspire Capital Fund Llc [Member]
Basis of Presentation [Line Items]
Stock Issued During Period, Value, New Issues	$ 500,000
Stock Issued During Period, Shares, Other	200,000
Aspire Capital Fund Llc [Member] | Maximum [Member]
Basis of Presentation [Line Items]
Sale of Stock, Consideration Received on Transaction	$ 15,000,000
iBio CMO [Member] | Eastern [Member]
Basis of Presentation [Line Items]
Stock Issued During Period, Shares, New Issues				3,500,000
Stock Issued During Period, Shares, Acquisitions				10,000,000	10,000,000
Common Stock, Par or Stated Value Per Share					$ 0.622
Class Of Warrants Or Rights Exercised				1,784,000
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.53
Proceeds From Capitalization Received				$ 15,000,000
Stock Issued During Period, Value, Acquisitions				$ 7,200,000

Summary of Significant Accoun33

Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Summary Of Significant Accounting Policies [Line Items]
Revenue from Grants	$ 9,000	$ 0	$ 9,000	$ 0

Fixed Assets and Capital Leas34

Fixed Assets and Capital Lease Obligations (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Jun. 30, 2015
Property, Plant and Equipment, Gross	$ 26,065	$ 40
Accumulated depreciation - assets under capital lease	(259)	0
Accumulated depreciation - other	(31)	(27)
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	(290)	(27)
Net fixed assets	25,775	13
Facility Under Capital Lease [Member]
Property, Plant and Equipment, Gross	20,000	0
Equipment Under Capital Lease [Member]
Property, Plant and Equipment, Gross	6,000	0
Facility Improvements [Member]
Property, Plant and Equipment, Gross	21	0
Office Equipment [Member]
Property, Plant and Equipment, Gross	$ 44	$ 40

Fixed Assets and Capital Leas35

Fixed Assets and Capital Lease Obligations (Details Textual) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Jan. 31, 2016	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Depreciation, Total	$ 263	$ 260	$ 11	$ 263	$ 3
iBio CMO LLC [Member] | Second Eastern Affilate [Member]
Lease Term				34 years
Capital Leased Assets [Member]
Depreciation, Total		$ 259		$ 259

Intangible Assets (Details)

Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Jun. 30, 2015
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross carrying value	$ 5,323	$ 5,281
Finite-Lived Intangible Assets, Accumulated Amortization	(3,184)	(2,921)
Net intangible assets	2,139	2,360
Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross carrying value	3,100	3,100
Finite-Lived Intangible Assets, Accumulated Amortization	(1,893)	(1,776)
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross carrying value	2,223	2,181
Finite-Lived Intangible Assets, Accumulated Amortization	$ (1,291)	$ (1,145)

Intangible Assets (Details Text

Intangible Assets (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 92	$ 88	$ 274	$ 266
Gain (Loss) on Disposition of Intangible Assets			33	47
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Gain (Loss) on Disposition of Intangible Assets	$ 16	$ 17	$ 33	$ 47
Maximum [Member] | Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life			23 years
Minimum [Member] | Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life			16 years

Significant Vendor (Details Tex

Significant Vendor (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Jun. 30, 2015	Apr. 30, 2014	Nov. 30, 2013	Jun. 30, 2013	Apr. 30, 2013
Significant Vendor [Line Items]
Accounts Payable, Current	$ 1,551,000		$ 1,551,000			$ 1,104,000
Accrued Liabilities, Current	647,000		647,000			159,000
Research and Development Expense	1,048,000	$ 815,000	2,303,000	$ 2,731,000
General and Administrative Expense Settlement	2,403,000	1,222,000	5,509,000	3,574,000
Earnings From Reversal of Expenses			1,900,000
Interest Expense, Total	323,000	0	323,000	0
Revenue, Net, Total	379,000	349,000	$ 673,000	1,535,000
Long Term Purchase Commitment Expire Date			Dec. 31, 2015
Settlement Agreement [Member]
Significant Vendor [Line Items]
Accounts Payable, Current	1,200,000		$ 1,200,000
Accrued Liabilities, Current	1,700,000		1,700,000
Research and Development Expense			1,040,000
Prepaid Expense	1,000,000		1,000,000				$ 1,000,000	$ 1,000,000		$ 1,000,000
General and Administrative Expense Settlement			700,000
Earnings From Reversal of Expenses			1,900,000
Interest Expense, Total			122,000
Amended Agreement [Member]
Significant Vendor [Line Items]
Revenue, Net, Total	357,000	348,000	635,000	1,535,000
Fraunhofer [Member]
Significant Vendor [Line Items]
Accounts Payable, Current	417,000		417,000			$ 445,000			$ 2,900,000
Research and Development Expense	357,000	$ 348,000	635,000	$ 1,535,000
Royalty Expense			200,000
Royalty Guarantees, Commitments, Amount	$ 4,000,000		$ 4,000,000		$ 3,000,000

Capital Lease Obligation (Detai

Capital Lease Obligation (Details) - USD ($)	Mar. 31, 2016	Jun. 30, 2015
March 31, 2017	$ 2,100,000
March 31, 2018	2,100,000
March 31, 2019	2,100,000
March 31, 2020	2,100,000
March 31, 2021	2,100,000
Thereafter	60,900,000
Total minimum lease payments	71,400,000
Less: current portion	25,308,000	$ 0
Capital Lease Obligations, Current	167,000	$ 0
Principal [Member]
March 31, 2017	166,649
March 31, 2018	179,693
March 31, 2019	193,758
March 31, 2020	208,924
March 31, 2021	225,277
Thereafter	24,500,699
Total minimum lease payments	25,475,000
Less: current portion	25,308,351
Capital Lease Obligations, Current	(166,649)
Interest [Member]
March 31, 2017	1,933,351
March 31, 2018	1,920,307
March 31, 2019	1,906,242
March 31, 2020	1,891,076
March 31, 2021	1,874,723
Thereafter	36,399,301
Total minimum lease payments	$ 45,925,000

Capital Lease Obligation (Det40

Capital Lease Obligation (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Capital Leases, Income Statement, Interest Expense	$ 323,000	$ 0	$ 323,000	$ 0
Sub Lease Expiration Period			34 years
Operating Leases, Rent Expense			$ 2,100,000
Capital Lease Obligation Description			The base rent under the sublease will be increased by any increase in the base rent under the ground lease as a result of such adjustments. In addition to the base rent, iBio CMO is required to pay, for each calendar year during the term, a portion of the total gross sales for products manufactured or processed at the facility, equal to 7% of the first $5,000,000 of gross sales, 6% of gross sales between $5,000,001 and $25,000,000, 5% of gross sales between $25,000,001 and $50,000,000, 4% of gross sales between $50,000,001 and $100,000,000, and 3% of gross sales between $100,000,001 and $500,000,000. However, if for any calendar year period from January 1, 2018 through December 31, 2019, iBio CMOs applicable gross sales are less than $5,000,000, or for any calendar year period from and after January 1, 2020, its applicable gross sales are less than $10,000,000

Stockholders' Equity (Details)

Stockholders' Equity (Details)	9 Months Ended
	Mar. 31, 2016$ / sharesshares
Class of Warrant or Right [Line Items]
Warrants, Outstanding as of July 1, 2015 | shares	6,633,324
Warrants, Exercised | shares	(1,904,000)
Warrants, Expired | shares	(4,699,324)
Warrants, Outstanding as of March 31, 2016 | shares	30,000
Weighted-average Exercise Price, Outstanding as of July 1, 2015 | $ / shares	$ 1.38
Weighted-average Exercise Price, Exercised | $ / shares	0.53
Weighted-average Exercise Price, Expired | $ / shares	2.09
Weighted-average Exercise Price, Outstanding as of March 31, 2016 | $ / shares	$ 0.53

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) - USD ($)	Jan. 13, 2016	May. 15, 2015	Apr. 30, 2016	Apr. 13, 2016	Jan. 25, 2016	Sep. 30, 2015	Mar. 31, 2016	Mar. 31, 2015	Jun. 30, 2015
Stockholders' Equity [Line Items]
Preferred Stock, Shares Authorized							1,000,000		1,000,000
Common Stock, Shares Authorized							175,000,000		175,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized							77,200,000
Common Stock, Shares, Issued							82,609,410		77,205,410
Common Stock, Shares, Outstanding							82,609,410		77,205,410
Proceeds from Warrant Exercises							$ 1,009,000	$ 867,000
Stock Issued During Period, Value, New Issues							$ 2,178,000
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 0.53		$ 1.38
Registration Common Stock							$ 15,000,000
Common Stock, Par or Stated Value Per Share							$ 0.001		$ 0.001
Class Of Warrants Or Rights Exercised							1,904,000
Warrant [Member]
Stockholders' Equity [Line Items]
Proceeds from Warrant Exercises						$ 63,000
Class Of Warrants Or Rights Exercised						120,000
Common Stock [Member]
Stockholders' Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period							30,000
Stock Issued During Period, Shares, New Issues							3,500,000
Stock Issued During Period, Value, New Issues							$ 4,000
Subsequent Event [Member]
Stockholders' Equity [Line Items]
Stock Issued During Period, Shares, New Issues			6,500,000	6,500,000
Stock Issued During Period, Value, New Issues			$ 4,000,000	$ 4,043,000
Subsequent Event [Member] | Stockholders [Member]
Stockholders' Equity [Line Items]
Stock Issued During Period, Shares, Other			6,500,000
Eastern Share Purchase Agreements [Member]
Stockholders' Equity [Line Items]
Proceeds from Warrant Exercises					$ 945,520
Stock Issued During Period, Value, New Issues					$ 2,178,000
Stock Issued During Period, Shares, Other	6,500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.53
Stock Issued During Period, Shares, Acquisitions	3,500,000
Common Stock, Par or Stated Value Per Share	$ 0.622
Class Of Warrants Or Rights Exercised					1,784,000
Maximum Common Stock Percentage	38.00%
Eastern Share Purchase Agreements [Member] | Stockholders [Member]
Stockholders' Equity [Line Items]
Common Stock, Par or Stated Value Per Share	$ 0.622
Aspire Capital Fund, LLC 2014 [Member]
Stockholders' Equity [Line Items]
Aggregate Common Stock Purchased		$ 15,000,000
Percentage Of Aggregate Shares Of Company							35.00%
Percentage Of Closing Price Of Common Stock							80.00%
Percentage Of Volume Weighted Average Price							97.00%
Stock Issued During Period, Shares, Other							150,000
Share Price							$ 0.40
Aspire Capital Fund, LLC 2015 [Member]
Stockholders' Equity [Line Items]
Commitment Shares Issued During Period		450,000
Maximum Amount Available For Purchase Of Shares							$ 15,000,000
Aspire Capital Fund, LLC 2015 [Member] | Aspirre Purchase Agreement 2015 [Member]
Stockholders' Equity [Line Items]
Percentage Of Common Stock Outstanding							19.99%
Commitment Shares Issued During Period							450,000
Stock Issued During Period, Shares, Other							15,343,406
Aspire Capital Fund Llc [Member]
Stockholders' Equity [Line Items]
Stock Issued During Period, Value, New Issues		$ 500,000
Stock Issued During Period, Shares, Other		200,000
Additional Purchase Of Shares		2,000,000

Earnings (Loss) Per Common Sh43

Earnings (Loss) Per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Basic and diluted numerator:
Net loss available to iBio, Inc. stockholders	$ (3,036)	$ (1,677)	$ (7,087)	$ (4,740)
Basic and diluted denominator:
Weighted-average common shares outstanding	81,158	72,989	78,587	69,913
Per Share Amount	$ (0.04)	$ (0.02)	$ (0.09)	$ (0.07)

Earnings (Loss) Per Common Sh44

Earnings (Loss) Per Common Share (Details Textual) - shares shares in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]
Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants	12.3	9.7	30,000	6.6

Share-Based Compensation (Detai

Share-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$ 297	$ 224	$ 940	$ 690
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	6	0	15	0
General and Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$ 291	$ 224	$ 925	$ 690

Share-Based Compensation (Det46

Share-Based Compensation (Details 1) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Mar. 31, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Options, Outstanding at beginning of the period	9,523,334
Stock Options, Granted	2,750,000
Stock Options, Outstanding at end of the period	12,273,334	9,523,334
Stock Options, Vested and, as of March 31, 2016, expected to vest	12,212,641
Stock Options, Exercisable as of March 31, 2016	7,455,024
Weighted-average Exercise Price, Outstanding at beginning of the period	$ 1.22
Weighted-average Exercise Price, Granted	1.64
Weighted-average Exercise Price, Outstanding at end of the period	1.31	$ 1.22
Weighted-average Exercise Price, Vested and, as of March 31, 2016, expected to vest	1.31
Weighted-average Exercise Price, Exercisable as of March 31, 2016	$ 1.31
Weighted-average Remaining Contractual Term (in years), Outstanding	6 years 7 months 6 days	6 years 7 months 6 days
Weighted-average Remaining Contractual Term (in years), Vested and, as of March 31, 2016, expected to vest	6 years 7 months 6 days
Weighted-average Remaining Contractual Term (in years), Exercisable as of March 31, 2016	5 years 3 months 18 days
Aggregate Intrinsic Value ,Outstanding	$ 479	$ 1,848
Aggregate Intrinsic Value, Vested and, as of March 31, 2016, expected to vest	479
Aggregate Intrinsic Value, Exercisable as of March 31, 2016	$ 417

Share-Based Compensation (Det47

Share-Based Compensation (Details 2)	9 Months Ended
	Mar. 31, 2016
Dividend yield	0.00%
Expected term (in years)	9 years
Minimum [Member]
Risk-free interest rate	1.83%
Volatility	109.49%
Maximum [Member]
Risk-free interest rate	2.13%
Volatility	112.17%

Share-Based Compensation (Det48

Share-Based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Millions	Sep. 04, 2015	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)		77,200,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)		2,900,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 0.62
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized (in Dollars)		$ 1.9
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition		2 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		2,750,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 1.64
Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period, Description		Plan was amended to increase the number of shares reserved for awards under the Plan from 10 million to 15 million
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)		10,000,000
Board Of Directors And Officers [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	2,750,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 1.64

Related Party Transactions (Det

Related Party Transactions (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015	Jun. 30, 2015
Related Party Transaction [Line Items]
Accounts Payable, Related Parties, Current	$ 183,000		$ 183,000		$ 153,000
Research and Development Expense	$ 1,048,000	$ 815,000	2,303,000	$ 2,731,000
Operating Leases, Rent Expense			$ 2,100,000
Common Stock, Par or Stated Value Per Share	$ 0.001		$ 0.001		$ 0.001
Class Of Warrants Or Rights Exercised			1,904,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.53		$ 0.53		$ 1.38
Stock Issued During Period, Value, New Issues			$ 2,178,000
Proceeds from Warrant Exercises			1,009,000	867,000
General and Administrative Expense [Member]
Related Party Transaction [Line Items]
Other General And Administrative Expense	$ 296,000		$ 374,000
Eastern Two Share Purchase Agreements [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, New Issues			10,000,000
Common Stock, Par or Stated Value Per Share	$ 0.622		$ 0.622
Class Of Warrants Or Rights Exercised			1,784,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.53		$ 0.53
Stock Issued During Period, Value, New Issues			$ 6,220,000
Proceeds from Warrant Exercises			$ 945,520
Eastern Capital Limited and its Affiliates [Member] | Retained Interest [Member]
Related Party Transaction [Line Items]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	70.00%		70.00%
Eastern Capital Limited and its Affiliates [Member] | iBio CMO LLC [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Due from (to) Related Party, Total	$ 15,000,000		$ 15,000,000
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	30.00%		30.00%
Second Eastern Affilate [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties, Current	$ 443,000		$ 443,000
Interest Expense, Debt	$ 323,000		$ 323,000
Second Eastern Affilate [Member] | iBio CMO LLC [Member]
Related Party Transaction [Line Items]
Lease Term			34 years
Stockholders [Member] | Standstill Agreements [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, New Issues			6,500,000
Director [Member] | Standstill Agreements [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Equity Method Investment, Ownership Percentage	38.00%		38.00%
Novici Biotech LLC [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties, Current	$ 183,000		$ 183,000		$ 153,000
Research and Development Expense	$ 244,000	$ 258,000	723,000	$ 738,000
Cost of Services, Total			28,882
Related Party [Member]
Related Party Transaction [Line Items]
Operating Leases, Rent Expense			$ 2,000

Commitments and Contingencies (

Commitments and Contingencies (Details Textual) - USD ($)	Jan. 14, 2014	Dec. 31, 2015	Jan. 31, 2014	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015	Jun. 30, 2015	Sep. 01, 2014	Dec. 30, 2013
Commitments and Contingencies [Line Items]
Research and Development Expense, Total				$ 1,048,000	$ 815,000	$ 2,303,000	$ 2,731,000
Long Term Purchase Commitment Expire Date						Dec. 31, 2015
Settlement Liabilities, Current				1,875,000		$ 1,875,000
Second Eastern Affilate [Member] | iBio CMO LLC [Member]
Commitments and Contingencies [Line Items]
Lease Term						34 years
Fraunhofer [Member]
Commitments and Contingencies [Line Items]
Research and Development Expense, Total				357,000	$ 348,000	$ 635,000	$ 1,535,000
Royalty Guarantees, Commitments, Amount		$ 3,000,000		$ 4,000,000		$ 4,000,000
Contractual Obligation		3,000,000
Other Commitments, Description						Under the terms of the TTA (described in Note 7 Significant Vendor) and for a period of 15 years, the Company shall pay Fraunhofer one percent (1%) of all receipts derived by the Company from sales of products produced utilizing the iBioLaunch or iBioModulator technology and ten percent (10%) of all receipts derived by the Company from licensing either of those technologies to third parties.
Commitments [Member]
Commitments and Contingencies [Line Items]
Research Services Agreements Value Fulfilling Commitment		$ 3,000,000
Termination of Research Services Agreement			$ 1,500,000
Research and Development Expense, Total			$ 500,000					$ 2,100,000
License Costs	$ 30,627
Initial license fee	20,000
Contractual Obligation, Due in Next Twelve Months										$ 78,000
Contractual Obligation, Due in Second Year									$ 161,754
Commitments [Member] | Minimum [Member]
Commitments and Contingencies [Line Items]
License Costs	25,000
Commitments [Member] | Maximum [Member]
Commitments and Contingencies [Line Items]
License Costs	$ 150,000

Segment Reporting (Details)

Segment Reporting (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015	Jun. 30, 2015
Segment Reporting Information [Line Items]
Net revenues	$ 379	$ 349	$ 673	$ 1,535
Research and development expenses	1,048	815	2,303	2,731
General and administrative expenses	2,403	1,222	5,509	3,574
Operating loss	(3,072)	(1,688)	(7,139)	(4,770)
Total assets	50,665		50,665		$ 12,494
iBio Brazil [Member]
Segment Reporting Information [Line Items]
Net revenues	0	0	0	0
Research and development expenses	0	0	0	0
General and administrative expenses	5	35	17	86
Operating loss	(5)	(35)	(17)	(86)
Total assets	23		23		46
iBio United States [Member]
Segment Reporting Information [Line Items]
Net revenues	379	349	673	1,535
Research and development expenses	1,048	815	2,303	2,731
General and administrative expenses	2,398	1,187	5,492	3,488
Operating loss	(3,067)	$ (1,653)	(7,122)	$ (4,684)
Total assets	$ 50,642		$ 50,642		$ 12,448